

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<i>Complete if Known</i>	
	<b>Application Number</b>	10/815,262
	<b>Filing Date</b>	March 31, 2004
	<b>First Named Inventor</b>	John F. Engelhardt
	<b>Group Art Unit</b>	1633
	<b>Examiner Name</b>	Kevin Hill
Sheet 1 of 2		Attorney Docket No: 875.074US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	"Application Serial No. 09/689,136, Examiner Interview Summary mailed 04-18-05", 3 pgs	
	"Application Serial No. 09/689,136, Examiner Interview Summary mailed 05-16-05", 3 pgs	
	"Application Serial No. 09/689,136, Examiner Interview Summary mailed 09-28-04", 3 pgs	
	"Application Serial No. 10/815,557, Examiner Interview Summary mailed 02-06-07", 4 pgs	
	"Application Serial No. 10/837,029, Examiner Interview Summary mailed 11-15-07", 3 pgs	
	"Application Serial No. 10/837,029, Response filed 11-19-09 to Non-Final Office Action mailed 06-23-09", 14 pgs	
	"Application Serial No. 11/301.601, Response filed 01-04-10 to Non-Final Office Action mailed 9-28-09", 12 pgs	
	"Application Serial No. 11/890,761, Final Office Action mailed 12-22-09", 15 pgs	
	"Application Serial No. 11/890,761, Response filed 04-14-09 to Restriction Requirement mailed 10-14-08", 7 pgs	
	"Application Serial No. 11/890,776, Restriction Requirement mailed 12-17-08", 8 pgs	
	"Australian Application Serial No. 2004227358, Response filed 10-22-09 to Examiner's Second Report dated 08-27-09", 16 pgs.	
	"European Application Serial No. 04749619.5, Communication dated 04-14-08", 5 pgs.	
	"European Application Serial No. 04749619.5, Communication dated 03-11-09", 4 pgs.	
	"European Application Serial No. 04749619.5, Communication dated 09-13-07", 1 pg.	
	"European Application Serial No. 04749619.5, Communication dated 11-09-09", 3 pgs.	
	"European Application Serial No. 04749619.5, Communication Noting Loss of Rights dated 11-28-08", 1 pg.	
	"European Application Serial No. 04749619.5, Response filed 02-06-09 to Communication dated 11-28-08", 14 pgs.	
	"European Application Serial No. 04749619.5, Response filed 10-04-07 to Communication dated 09-13-07", 3 pgs.	
	"European Application Serial No. 04749619.5, Response filed 09-21-09 to Office Action mailed 03-11-09", 19 pgs.	
	"International Application Serial No. PCT/US2004/010045, International Search Report mailed 01-10-05", 6 pgs.	
	DENBY, L., et al., "Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation.", <u>Gene Therapy</u> , 12(20), (Oct., 2005), 1534-8	
	JENNINGS, K., et al., "Proteasome Inhibition Enhances AAV-Mediated Transgene Expression in Human Synoviocytes <i>in Vitro</i> and <i>in Vivo</i> ", <u>Molecular Therapy</u> , 11(4), (Apr., 2005), 600-607	
	JOHNSON, J. S., et al., "Enhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus", <u>Journal of Virology</u> , 83(6), (2009), 2632-2644	
	KIYOMIYA, K-I, et al., "Proteasome is a Carrier to Translocate Doxorubicin From Cytoplasm into Nucleus", <u>Life Sciences</u> , 62(20), (1998), 1853-1860	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<i>Complete if Known</i>	
	<b>Application Number</b>	10/815,262
	<b>Filing Date</b>	March 31, 2004
	<b>First Named Inventor</b>	John F. Engelhardt
	<b>Group Art Unit</b>	1633
	<b>Examiner Name</b>	Kevin Hill
Sheet 2 of 2	Attorney Docket No: 875.074US1	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	YAN, Z., et al., "Ubiquitination of Both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors", <u>Journal of Virology</u> , 76(5), (2002), 2043-2053	

EXAMINER

/Kevin Hill/

DATE CONSIDERED

05/24/2010

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/